WO2007069204A2 - Composition a base de plante officinale antivirale, virucide et immunomodulatrice et procede associe pour le traitement de maladies virales, en particulier de l'infection par le vih - Google Patents

Composition a base de plante officinale antivirale, virucide et immunomodulatrice et procede associe pour le traitement de maladies virales, en particulier de l'infection par le vih Download PDF

Info

Publication number
WO2007069204A2
WO2007069204A2 PCT/IB2006/054804 IB2006054804W WO2007069204A2 WO 2007069204 A2 WO2007069204 A2 WO 2007069204A2 IB 2006054804 W IB2006054804 W IB 2006054804W WO 2007069204 A2 WO2007069204 A2 WO 2007069204A2
Authority
WO
WIPO (PCT)
Prior art keywords
vol
composition
antiviral
immunomodulant
gummifera
Prior art date
Application number
PCT/IB2006/054804
Other languages
English (en)
Other versions
WO2007069204A3 (fr
Inventor
Christian Zaranaina
Original Assignee
Massimelli, Daniele Maria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massimelli, Daniele Maria filed Critical Massimelli, Daniele Maria
Publication of WO2007069204A2 publication Critical patent/WO2007069204A2/fr
Publication of WO2007069204A3 publication Critical patent/WO2007069204A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger

Definitions

  • the present invention relates to an antiviral, virucidal and immunomodulant composition based on officinal plants.
  • the present invention relates to a method for treating viral origin diseases using the new composition according to the invention, particularly for the treatment of HIV infection.
  • HIV acquired immune-deficiency syndrome
  • T cells lymphocyte cells of the immune system
  • the target of the HIV virus is a specific receptor present in the lymphocyte T cell called CD4.
  • CD4 a specific receptor present in the lymphocyte T cell
  • the virus penetrates the cell through the external shell and the RNA, and, by way of the "inverse transcribe" enzyme, is transcribed to the form of the DNA molecule.
  • Part of the viral DNA inserts itself in the genetic material of the cell and generates other viral particles.
  • the principal target cells of the HIV virus are the lymphocytes, the macrophages and some cells of the central nervous system.
  • the virus In most cases, the virus, once it penetrates the T cells, remains dormant for a certain period of time. However, once it has activated itself, the virus quickly destroys the T cells, damaging the immune system and causing immunodeficiency. This is the stage when the symptoms of AIDS become evident.
  • the associated therapies include a combination of inhibitors of the protease and the inverse transcribe (enzyme that promotes the transcription of the viral RNA - genetic patrimony of the HIV virus - in the DNA and, therefore, it allows successive integration in the cellular DNA). The purpose is to reduce the viral charge and to "slow down" the replication of the virus.
  • the publication no. US2005/0238736 of Mitra, et al. describes a natural immunomodulant composition for the treatment of immunodeficiency, comprising of vegetable extracts (Symplocos racemosa, Prosopis glandulosa, etc.), and it describes its method of preparation and treatment procedures of diseases such as AIDS, hepatitis and cancer.
  • compositions to be used for pharmaceutical and dietary purposes comprising of vegetable extracts to be administered separately or sequentially to humans or to animals.
  • the publication mentioned two kinds of curcuma (Curcuma domestica and Curcuma xanthorrhiza), the vinca (Vinca minor) and Eucalyptus globulus.
  • Publication CN1473610 of MEN CUIPING describes a medicine based on vegetable extracts for the treatment of cancer of various organs (liver, stomach, lungs). Among the plants used, the Albizia species is mentioned.
  • Publication US/4871540 of KOHMA YASYHIKO describes a biologically active substance comprising a particular glycolipid obtained from extracts of tissues of the plant Zeaaria. This substance stimulates the production of antibodies and lymphocytes. It has anti-tumor properties and is useful in the prevention and treatment of AIDS, hepatitis and other diseases related to immunodeficiency.
  • Curcuma longa (or Long curcuma) is an officinal plant long known for its anti- inflammatory, antiviral and internal cleansing properties.
  • Eucalyptus globulus is known mainly for the essential oil extracted from its leaves through distillation. Besides the well known secretional and expectorant properties, the essential oil has also been recognized recently to have important virostatic and bactericidal effects.
  • Vinca rosea (or Catharanthus roseus or pink periwinkle) is a native plant of
  • Albizia gummifera is a plant known especially in Chinese medicine and its extracts are used, for example, to formulate medicines for cancer treatment.
  • Zearium (or corn), one of the most known and diffused plants in the world, beside having an enormous importance in the food field, it is further known in the medical field for its numerous properties, including: energizing, analgesic, haemostatic, emollient, cholesterol lowering, hypoglycemic, gall fluidizer properties, etc.
  • the antiviral activity is generically understood as the ability to fight, that is, to inhibit or to prevent, viral replication.
  • a virucidal agent possesses, in addition, the capability to destroy the virus.
  • An immunomodulant action is instead an intervention on the immune system, set to amplify and/or to modify one or more of its functions.
  • Such plants have synergistic antiviral, virucidal and immunomodulant effects when used concurrently. Such a mixture is, therefore, particularly useful in the treatment of diseases of viral origin, particularly in HIV infection cases, but also in cases of hepatitis, cancer, etc.
  • the purpose of the present invention is to provide a new anti- viral, virucidal and immunomodulant composition made of substances of vegetable origin derived from the six kinds of aforementioned plants, whose mixture is critical in obtaining such antiviral, virucidal and and immunomodulant effects.
  • the purpose of the present invention is also to provide a method which is effective and free of side effects for the treatment of viral origin diseases.
  • Another purpose of the present invention is to provide an effective method for the treatment of the HIV infection which is free of side effects.
  • a further purpose of the present invention is to provide a method for an HIV infection treatment that results in a simplified implementation regarding both the preparation and the dispensing of the medicine.
  • composition generated by the synergistic effect of the mixture of the six aforementioned plants, it was observed at the greatest advantage, that the composition is not only able to help the immune system to resist to the multiplication of the HIV virus, but also to destroy the virus, as well as to stimulate and to modulate an effective immune system response.
  • composition according to the invention includes, at great advantage, substances of vegetable origin extracted from the six kinds of plants here listed: Curcuma longa, Eucalyptus globulus; Vinca rosea; Illicium verum; Albizia gummifera; Zea perennial.
  • composition according to the invention comprises, at least one but preferably all of the following fillers:
  • the components of the composition are illustrated according to a preferred embodiment of the invention prepared in the form of an infusion, according to a standard procedure, using the six plant species and specified fillers.
  • the quantities, expressed in percentage of volume, refer to the processed vegetables in the form of freeze-dried extract, dried or ground.
  • the officinal plants, the object of the composition can be mixed at great advantage, as illustrated on Table A, in three sub-compositions, from which it is possible to prepare three infusions.
  • - infusion 1 made of Curcuma longa and Eucalyptus globulus (fillers: corn starch, animal gelatin, colina);
  • - infusion 2 made of Vinca rosea and Illicium verum (fillers: corn starch, animal gelatin, folic acid, vitamins B2 and B6);
  • Curcuma longa from 8 to 12% vol
  • Eucalyptus globulus from 28 to 32% vol
  • Vinca rosea from 3 to 7% vol
  • Illicium verum from 8 to 12% vol
  • Albizia gurnmifera from 10 to 14% vol
  • Zea corpos from 23 to 27% vol.
  • each infusion can be obtained by boiling the vegetable components for 10 minutes, in measure of about 5 grams of vegetable parts for a liter of water, together with the relative filler substances.
  • composition according to the invention can also be used for the preparation of extracts, tinctures and freeze-dried extracts, as well as tablets or pills prepared using compressed powder, preferably according to the composition as indicated on Table A.
  • the aforesaid methods of dispensing have in common the advantage of simplifying considerably the therapeutic treatment, because they can be easily administered throughout the day and/or within a multiple day period.
  • the three sub-compositions 1, 2 and 3 can be also be prepared as tablets or pills to greatest advantage.
  • a test was conducted with the purpose of evaluating the antiviral action of the composition according to the invention.
  • the test was conducted on cells MT4 infected by the HIV virus (HIV2 (ROD); HIV-I (HIB)), and an inhibitory effect regarding the proliferation of the virus in the infected MT4 cells was observed.
  • HIV2 HIV2
  • HIV-I HIV-I
  • Infusions 1, 2 and 3 can, for example, be taken daily for a period of 30 days, preferably many times a day at pre-determined schedules, each depending on the infusion, in quantity between 25 and 50 cl. per day for each infusion. It was observed that such diversified dispensing obtains an effective antiviral, virucidal and immunomodulant action.
  • Numerous tests and essays have been conducted with the purpose of identifying the possible mechanism that is at the base of the beneficial effects obtained by taking the composition according to the invention. Using the obtained results, the inventor was able to make the following observations: viruses are able to "deceive" the victim's immune system by "disguising" some of the viral proteins. It was observed, particularly for the HIV virus, that as a first step by the immune system, this phenomenon does not allow the immune system to develop specific antibodies for all viral antigens. The organism, therefore, does not possess defenses sufficiently specific and effective to defeat the virus.
  • the inventor has found the production of a new type of T4 cells of the immune system, that he/she has called A. P. C. cells. Such cells have highlighted the presence of a characteristic protein, denominated ISA 27.1.
  • the vegetable protein interacts bio-electrically with the virus, for example the HIV virus, causing its destruction.
  • the virus for example the HIV virus
  • the dispersion of the viral components occurs in the blood.
  • the immune system is able, by consequence, to come into contact with all the parts of the virus, including the components previously "disguised,” and, as a result, it begins to modulate new effective defenses from the "new knowledge" acquired.
  • the immune system differentiates a new type of immune T4 cells, also called A. P. C. cells, characterized by a new protein called ISA 27.1.
  • This protein allows the new T4 cells to recognize as antigens all the viral proteins, including those normally “disguised” in respect to the immune system, and, therefore, to attack and destroy the virus.
  • composition according to the invention can be considered a valid and actual cure against diseases of viral origin, including HIV infection.
  • the method for the treatment of the HIV infection using the composition according to the invention in addition to having revealed itself as being effective against the HIV infection, has also shown itself to be free of side effects and easy to use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La présente invention concerne une composition antivirale, virucide et immunomodulatrice constituée des plantes officinales Curcuma longa, Eucalyptus globulus, Vinca rosea, Illicium verum, Albizia gummifera, et Zea mais, et le procédé associé pour le traitement de maladies d'origine virale, en particulier l'infection par le VIH.
PCT/IB2006/054804 2005-12-14 2006-12-13 Composition a base de plante officinale antivirale, virucide et immunomodulatrice et procede associe pour le traitement de maladies virales, en particulier de l'infection par le vih WO2007069204A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITTO20050869 ITTO20050869A1 (it) 2005-12-14 2005-12-14 Composizione antivirale, virucida ed immunomodulante a base di piante officinali e relativo metodo per il trattamento delle malattie di origine virale, in particolare dell'infezione da hiv.
ITTO2005A000869 2005-12-14

Publications (2)

Publication Number Publication Date
WO2007069204A2 true WO2007069204A2 (fr) 2007-06-21
WO2007069204A3 WO2007069204A3 (fr) 2007-10-25

Family

ID=38057552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/054804 WO2007069204A2 (fr) 2005-12-14 2006-12-13 Composition a base de plante officinale antivirale, virucide et immunomodulatrice et procede associe pour le traitement de maladies virales, en particulier de l'infection par le vih

Country Status (2)

Country Link
IT (1) ITTO20050869A1 (fr)
WO (1) WO2007069204A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062260A1 (fr) * 2008-11-29 2010-06-03 The Thailand Research Fund Inhibition de l’interaction d’un virus et d’une cellule cible
CN110279752A (zh) * 2019-06-06 2019-09-27 广西医科大学 速生桉叶提取物及其制备方法和抗hiv应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB952588A (en) * 1959-06-16 1964-03-18 Anthony Lipton A material having uterine contractant activity and a process for its extraction from the plants of the genus albizia
DE19716660A1 (de) * 1997-04-22 1998-10-29 Schwabe Willmar Gmbh & Co Zubereitungen, insbesondere pharmazeutische, und Arzneiformen auf pflanzlicher Basis zur Bekämpfung von Heliobacter pylori-Infektionen
WO2002007744A1 (fr) * 2000-07-20 2002-01-31 Anne Marie Pierrette Giraud Association d'huiles essentielles et applications therapeutiques
US20020173436A1 (en) * 2000-09-20 2002-11-21 Steffen Sonnenberg Multiphase soaps

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4979181B2 (ja) * 2003-01-31 2012-07-18 株式会社ヤクルト本社 グリケーション阻害剤及びその利用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB952588A (en) * 1959-06-16 1964-03-18 Anthony Lipton A material having uterine contractant activity and a process for its extraction from the plants of the genus albizia
DE19716660A1 (de) * 1997-04-22 1998-10-29 Schwabe Willmar Gmbh & Co Zubereitungen, insbesondere pharmazeutische, und Arzneiformen auf pflanzlicher Basis zur Bekämpfung von Heliobacter pylori-Infektionen
WO2002007744A1 (fr) * 2000-07-20 2002-01-31 Anne Marie Pierrette Giraud Association d'huiles essentielles et applications therapeutiques
US20020173436A1 (en) * 2000-09-20 2002-11-21 Steffen Sonnenberg Multiphase soaps

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COWAN MARJORIE MURPHY: "Plant products as antimicrobial agents" CLINICAL MICROBIOLOGY REVIEWS, vol. 12, no. 4, October 1999 (1999-10), pages 564-582, XP002441478 ISSN: 0893-8512 *
DATABASE WPI Week 200463 Derwent Publications Ltd., London, GB; AN 2004-645577 XP002441473 & JP 2004 250445 A (YAKULT HONSHA KK) 9 September 2004 (2004-09-09) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062260A1 (fr) * 2008-11-29 2010-06-03 The Thailand Research Fund Inhibition de l’interaction d’un virus et d’une cellule cible
CN110279752A (zh) * 2019-06-06 2019-09-27 广西医科大学 速生桉叶提取物及其制备方法和抗hiv应用

Also Published As

Publication number Publication date
ITTO20050869A1 (it) 2007-06-15
WO2007069204A3 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
Wasser Reishi or ling zhi (Ganoderma lucidum)
CN102145158B (zh) 生姜与丁香组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途
Siveen et al. Augmentation of humoral and cell mediated immune responses by Thujone
Prajapati et al. An exhaustive comprehension of the role of herbal medicines in Pre-and Post-COVID manifestations
Singh et al. Recent patent technologies of Tinospora cordifolia for anti-diabetic potential: a review
US20060172021A1 (en) Herbal compositions for the prevention or treatment of symptoms of stress and infection
WO2007069204A2 (fr) Composition a base de plante officinale antivirale, virucide et immunomodulatrice et procede associe pour le traitement de maladies virales, en particulier de l'infection par le vih
CN114470042B (zh) 一种防治动物肝损伤的组合物及其制备方法和用途
CN102091313B (zh) 紫苏叶与生姜组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途
CN102091312B (zh) 生姜与花椒组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途
JP2958198B2 (ja) 鎮痛用医薬組成物
CN100363043C (zh) 一种治疗风湿或类风湿的中药组合物及其制备方法
JP2003104901A (ja) 健康指向性組成物
CN106074662A (zh) 一种具有解酒保肝作用的姜黄组合物
Ghate et al. Spices, Unpacked Diet, Bio Actives and Immunity: Indian Health & Pandemic
Hidayat et al. Potential of Meniran (Phyllanthus niruri L.) and Sambiloto (Andrographis paniculata) as a Supplement to the Management of Coronavirus Disease 2019 (COVID-19)
Das G1-4A, an arabinogalactan polysaccharide derived from Tinospora cordifolia (Thunb.) Miers: a natural immunomodulator
WO2018228431A1 (fr) Applications de triterpène saponines extraites de la racine de cimicifuga foetida, d'actéine et de désoxy-actéine
EP2402021A1 (fr) Composition pharmaceutique pour traiter ou soulager les maladies intestinales inflammatoires
CN101185668A (zh) 一种新的防治艾滋病及保肝解毒制剂
Thakur et al. Colchicum autumnale (Suranjan): A cytotoxic plant with anti-arthritis properties
CN105246472B (zh) 含有鸟氨酸和/或门冬氨酸的组合物及其应用
CN101199574A (zh) 紫草科琉璃草属植物的提取物在制备抗炎镇痛药物中的用途
Al Azzam et al. Nigella sativa L. as a potential natural product for the treatment of COVID-19
CN107496485A (zh) 毛大丁草的益肝作用及应用技术

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06842478

Country of ref document: EP

Kind code of ref document: A2